The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

Sleep apnea can significantly increase health risks ... The drug's active ingredient, tirzepatide, is marketed as Zepbound for weight loss and Mounjaro as a diabetes treatment. Zepbound's side effects ...